NEWARK, Del., Jan. 27, 2012 /PRNewswire/ -- iBio, Inc. (NYSE AMEX: IBIO) announced today that the NYSE Amex confirmed positive resolution of the Company's previously noted listing deficiency with respect to Section 1003(1)(iv) of the NYSE Amex Company Guide.

About iBio, Inc.

iBio develops and offers product applications of its iBioLaunch(TM) platform, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The technology has been applied successfully to proteins difficult or impossible to produce with other methods, as well as proteins representative of most important classes of biologic pharmaceuticals. Advantages of the iBioLaunch platform over other systems include enablement of rapid development and validation of modular, scalable, and optionally robotic, multi-product manufacturing facilities; production time measured in weeks instead of months or more; product entry that is unconstrained by traditional process patents; and significantly lower capital and operating costs for comparable production. Further information is available at: www.ibioinc.com.

Forward-Looking Statements

Statements included in this news release related to iBio, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission. 


    Contacts:

    Corporate:                Investor:
    ----------              ---------
    Robert Erwin, President   Douglas Beck, CFO
    iBio, Inc.                iBio, Inc.
    302-355-2335              302-355-0923
    rerwin@ibioinc.com        ir@ibioinc.com

SOURCE iBio, Inc.